

Bimekizumab-bkzx Therapeutic Cheat Sheet

COMPILED BY: ALEXIS E. CARRINGTON, MD | REVIEWED BY: ADAM FRIEDMAN, MD

TRADE NAME

- > BIMZELX®

MECHANISM OF ACTION^{1,2}

- > Bimekizumab is an IgG1 antibody that inhibits proinflammatory cytokines IL-17A and IL-17F, both of which are key in the pathogenesis of plaque psoriasis. Evidence suggests inhibiting both of these cytokines is more effective at treating plaque psoriasis than inhibiting IL-17A alone.

FDA APPROVED FOR¹

- > Adults with moderate to severe plaque psoriasis

OFF-LABEL USES³⁻⁷

- > Psoriatic arthritis
- > Lichen planus
- > Nail psoriasis
- > Axial spondyloarthritis
- > Hidradenitis suppurativa
- > Palmoplantar pustular psoriasis

DOSING¹

- > Loading dose: 320 mg (two 160 mg injections) subcutaneous injection at Weeks 0, 4, 8, 12, and 16
 - > Maintenance dose: 160 mg injection every 8 weeks*
- *For patients weighing ≥ 120 kg, consider a dose of 320 mg every 4 weeks after week 16.

SIDE EFFECTS¹

Most common side effects of bimekizumab include:

- > Upper respiratory infections (15%)
- > Oral candidiasis (9%)
- > Fungal infections (3%)
- > Pain at the injection site (3%)
- > Gastroenteritis (2%)
- > Herpes simplex infections (1%)
- > Fatigue (1%)
- > Acne (1%)
- > Dermatitis/contact dermatitis (<1%)

WARNINGS¹

- > May increase the risk of suicidal ideation*
- > Increased risk infections, including tuberculosis (TB)
- > Elevated liver enzymes
- > Increased risk of irritable bowel disease (IBD)

*This warning came from a trial study where few study subjects without a history of suicidal ideation and treated with bimekizumab had a higher rate of suicidal ideation than those with placebo (1.3% vs. 0.6%). Overall, it has not been established that bimekizumab can cause suicidal ideation or behavior.

CONTRAINDICATIONS¹

- > Patients with known hypersensitivity to bimekizumab or any of the excipients in the formulation

PREGNANCY & BREASTFEEDING¹

- > There is insufficient data on the risk of birth defects or miscarriage in pregnant women
- > Bimekizumab may be transmitted from the mother to fetus
- > There is no data on the presence of bimekizumab in animal or human milk or on its effect on breastfeeding infants

MONITORING¹

Baseline:

- > Psychiatric history
- > Quantiferon gold for TB followed by a yearly TB test
- > Pregnancy test for female patients of child bearing potential
- > CBC
- > CMP to evaluate for liver enzymes
- > HBV and HCV studies
- > HIV

REFERENCES

1. BIMZELX® (Bimekizumab) [Package Insert]. Brussels, Belgium: UCB Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761151s0001bl.pdf
2. Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. *Lancet*. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4. Erratum in: *Lancet*. 2021 Mar 27;397(10280):1182. PMID: 33549192.
3. Tanaka Y, Shaw S. Bimekizumab for the treatment of psoriatic arthritis. *Expert Rev Clin Immunol*. 2023 Nov 1. doi: 10.1080/1744666X.2023.2277266. Epub ahead of print. PMID: 37909894.
4. Deodhar A, Machado PM, Mørup M, Taieb V, Willems D, Orme M, Pritchett D, Gensler LS. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis. *Rheumatology (Oxford)*. 2023 Nov 8;kead598. doi: 10.1093/rheumatology/kead598. Epub ahead of print. PMID: 37947318.
5. Hwang JK, Grover C, Iorizzo M, Lebwohl MG, Piraccini BM, Rigopoulos DG, Lipner SR. Nail Psoriasis & Nail Lichen Planus: Updates on Diagnosis & Management. *J Am Acad Dermatol*. 2023 Nov 23:S0190-9622(23)03224-3. doi: 10.1016/j.jaad.2023.11.024. Epub ahead of print. PMID: 38007038.
6. Malvaso D, Calabrese L, Chiricozzi A, Antonelli F, Coscarella G, Rubegni P, Peris K. IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa. *Pharmaceutics*. 2023 Oct 11;15(10):2450. doi: 10.3390/pharmaceutics15102450. PMID: 37896210; PMCID: PMC10609891.
7. Passeron T, Perrot JL, Jullien D, Goujon C, Ruer M, Boyé T, Villani AP, Quiles Tsimaratos N. Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab. *JAMA Dermatol*. 2023 Dec 6:e235051. doi: 10.1001/jamadermatol.2023.5051. Epub ahead of print. PMID: 38054800; PMCID: PMC10701662.